Do Vγ2Vδ2 T cells influence HIV disease progression?

Clinical Infectious Diseases

Volumn 46, Issue 9, 2008, Pages 1473-1475

  Nunnari, Giuseppe ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 12; LYMPHOCYTE ANTIGEN RECEPTOR;

CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; VIRUS REPLICATION; CD4+ T LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS;

EID: 42549143212     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587108     Document Type: Note

References (14)

1. Gougeon ML, Malkovsky M, Casetti R, Agrati C, Poccia F. Innate T cell immunity to HIV-infection: immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention? Vaccine 2002; 20:1938-41.
2. Poccia F, Battistini L, Cipriani B, et al. Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J Infect Dis 1999; 180:858-61.
3. Poccia F, Cipriani B, Vendetti S, et al. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes. J Immunol 1997; 159:6009-17.
4. Li H, Peng H, Ma P, Pauza D, Shao Y. Association between Vγ2Vδ2 T cells and disease progression after infection with closely-related viral strains of HIV in China. Clin Infect Dis 2008; 46:1466-72 (in this issue).
5. + lymphocyte subsets during HIV infection. Clin Exp Immunol 1989; 75:206-10.
6. De Maria A, Ferrazin A, Ferrini S, Ciccone E, Terragna A, Moretta L. Selective increase of a subset of T cell receptor gamma delta T lymphocytes in the peripheral blood of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1992; 165:917-9.
7. De Paoli P, Gennari D, Martelli P, et al. A subset of gamma delta lymphocytes is increased during HIV-1 infection. Clin Exp Immunol 1991; 83:187-91.
8. Boullier S, Dadaglio G, Lafeuillade A, Debord T, Gougeon ML. V delta 1 T cells expanded in the blood throughout HIV infection display a cytotoxic activity and are primed for TNF-alpha and IFN-gamma production but are not selected in lymph nodes. J Immunol 1997; 159:3629-37.
9. Kosub DA, Lehrman G, Milush JM, et al. Gamma/delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian im munodeficiency virus infections. J Virol 2008; 82:1155-65.
10. Bordon J, Evans PS, Propp N, Davis CE Jr, Redfield RR, Pauza CD. Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis 2004; 189:1482-6.
11. Poles MA, Barsoum S, Yu W, et al. Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy. J Virol 2003; 77:10456-67.
12. Poccia F, Boullier S, Lecoeur H, et al. Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol 1996; 157:449-61
13. Martini F, Poccia F, Goletti D, et al. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. J Infect Dis 2002; 186:847-50.
14. Martini F, Urso R, Gioia C, et al. Gammadelta T-cell anergy in human immunodeficiency virus-infected persons with opportunistic infections and recovery after highly active antiretroviral therapy. Immunology 2000; 100:481-6.